Literature DB >> 15470265

The wrickkened pathways of FGF23, MEPE and PHEX.

Peter S N Rowe1.   

Abstract

The last 350 years since the publication of the first medical monograph on rickets (old English term wrickken) (Glisson et al., 1651) have seen spectacular advances in our understanding of mineral-homeostasis. Seminal and exciting discoveries have revealed the roles of PTH, vitamin D, and calcitonin in regulating calcium and phosphate, and maintaining healthy teeth and skeleton. However, it is clear that the PTH/Vitamin D axis does not account for the entire picture, and a new bone-renal metabolic milieu has emerged, implicating a novel set of matrix proteins, hormones, and Zn-metallopeptidases. The primary defects in X-linked hypophosphatemic rickets (HYP) and autosomal-dominant hypophosphatemic rickets (ADHR) are now identified as inactivating mutations in a Zn-metalloendopeptidase (PHEX) and activating mutations in fibroblast-growth-factor-23 (FGF23), respectively. In oncogenic hypophosphatemic osteomalacia (OHO), several tumor-expressed proteins (MEPE, FGF23, and FRP-4) have emerged as candidate mediators of the bone-renal pathophysiology. This has stimulated the proposal of a global model that takes into account the remarkable similarities between the inherited diseases (HYP and ADHR) and the tumor-acquired disease OHO. In HYP, loss of PHEX function is proposed to result in an increase in uncleaved full-length FGF23 and/or inappropriate processing of MEPE. In ADHR, a mutation in FGF23 results in resistance to proteolysis by PHEX or other proteases and an increase in half-life of full-length phosphaturic FGF23. In OHO, over-expression of FGF23 and/or MEPE is proposed to result in abnormal renal-phosphate handling and mineralization. Although this model is attractive, many questions remain unanswered, suggesting a more complex picture. The following review will present a global hypothesis that attempts to explain the experimental and clinical observations in HYP, ADHR, and OHO, plus diverse mouse models that include the MEPE null mutant, HYP-PHEX transgenic mouse, and MEPE-PHEX double-null-mutant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470265      PMCID: PMC3361894          DOI: 10.1177/154411130401500503

Source DB:  PubMed          Journal:  Crit Rev Oral Biol Med        ISSN: 1045-4411


  160 in total

1.  Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway.

Authors:  Tetsuo Yamashita; Morichika Konishi; Ayumi Miyake; Ken-ichi Inui; Nobuyuki Itoh
Journal:  J Biol Chem       Date:  2002-05-24       Impact factor: 5.157

Review 2.  Molecular pathogenesis of hypophosphatemic rickets.

Authors:  Suzanne M Jan de Beur; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

3.  Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.

Authors:  Shiguang Liu; Rong Guo; Qisheng Tu; L Darryl Quarles
Journal:  J Biol Chem       Date:  2001-11-16       Impact factor: 5.157

4.  M13 endopeptidases: New conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish.

Authors:  Laurent Bianchetti; Claudine Oudet; Olivier Poch
Journal:  Proteins       Date:  2002-06-01

5.  Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts.

Authors:  D L Thompson; Y Sabbagh; H S Tenenhouse; P C Roche; M K Drezner; J L Salisbury; J P Grande; E M Poeschla; R Kumar
Journal:  J Bone Miner Res       Date:  2002-02       Impact factor: 6.741

Review 6.  Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-07       Impact factor: 2.894

7.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

8.  Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism.

Authors:  Suzanne M Jan De Beur; Richard B Finnegan; John Vassiliadis; Brian Cook; Dana Barberio; Scott Estes; Partha Manavalan; Joseph Petroziello; Stephen L Madden; Justin Y Cho; Rajiv Kumar; Michael A Levine; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2002-06       Impact factor: 6.741

Review 9.  New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.

Authors:  Rajiv Kumar
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

10.  Comparison of inhibitory activity on calcium phosphate precipitation by acidic proline-rich proteins, statherin, and histatin-1.

Authors:  N Tamaki; T Tada; M Morita; T Watanabe
Journal:  Calcif Tissue Int       Date:  2002-06-13       Impact factor: 4.333

View more
  50 in total

Review 1.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

2.  Human stanniocalcin-1 or -2 expressed in mice reduces bone size and severely inhibits cranial intramembranous bone growth.

Authors:  Jennifer Johnston; Yudith Ramos-Valdes; Lee-Anne Stanton; Sadia Ladhani; Frank Beier; Gabriel E Dimattia
Journal:  Transgenic Res       Date:  2010-02-20       Impact factor: 2.788

Review 3.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 4.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

5.  Modulation of extracellular matrix protein phosphorylation alters mineralization in differentiating chick limb-bud mesenchymal cell micromass cultures.

Authors:  Adele L Boskey; Stephen B Doty; Valery Kudryashov; Philipp Mayer-Kuckuk; Rani Roy; Itzhak Binderman
Journal:  Bone       Date:  2008-02-13       Impact factor: 4.398

6.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

7.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

Review 8.  Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

Authors:  James B Wetmore; L Darryl Quarles
Journal:  Nat Clin Pract Nephrol       Date:  2008-10-28

9.  PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets.

Authors:  Céline Gaucher; Odile Walrant-Debray; Thy-Minh Nguyen; Laure Esterle; Michèle Garabédian; Frédéric Jehan
Journal:  Hum Genet       Date:  2009-02-15       Impact factor: 4.132

10.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.